Kidney Cancer PBMC

Kidney Cancer PBMC for Tumor Immunology and Immuno-Oncology Research

Kidney Cancer PBMC products are sourced from IRB-consented donors clinically diagnosed with kidney cancer and processed within 24 hours of collection under standardized SOPs. These cryopreserved peripheral blood mononuclear cells are stored in CryoStor® CS10 and shipped on dry ice. Research Use Only (RUO).

Tumor Immunology and Why PBMC

  • Most kidney cancers are renal cell carcinoma, and clear cell RCC is the dominant histology; papillary and chromophobe subtypes are biologically distinct.
  • Clear cell RCC is characterized by loss of VHL function, which stabilizes hypoxia-inducible factors and drives a strongly VEGF-dependent, highly vascular tumor phenotype.
  • RCC is among the more densely immune-infiltrated solid tumors and is clinically responsive to immune checkpoint blockade, including combinations of checkpoint inhibitors and with VEGF-directed tyrosine kinase inhibitors.
  • Circulating T cells in advanced disease commonly show activation and exhaustion-associated phenotypes, and peripheral immune composition is widely studied as a correlate of checkpoint inhibitor response.
  • PBMCs provide viable effector and regulatory populations for immunophenotyping, TCR repertoire analysis, and functional cytotoxicity or suppression assays; plasma and serum cannot support these readouts.
  • Donor-matched PBMCs are also used as autologous effector cells in co-culture and ex vivo checkpoint blockade models.

Donor Stratification Available

  • Histology where documented: clear cell, papillary, or chromophobe renal cell carcinoma
  • Stage at diagnosis and presence of metastatic disease
  • Treatment status: treatment-naive, on immune checkpoint inhibitor, on VEGF-targeted tyrosine kinase inhibitor, or post-nephrectomy
  • Response category where documented: responding, progressing, or refractory
  • Renal function and relevant comorbidities
  • Age, sex, and self-reported race/ethnicity
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO), cryopreserved PBMCs
  • Clinically confirmed kidney cancer donors
  • Processed within 24 hours of collection
  • Stored using CryoStor® CS10 freezing media
  • Custom aliquots available; shipped on dry ice
  • IRB-approved protocols and electronic informed consent
  • Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

  • Verified kidney cancer diagnosis
  • Donor demographics: age, sex assigned at birth, race/ethnicity
  • Self-reported allergies and infectious disease history
  • Histology, stage, and treatment history where available
  • Additional kidney cancer-specific data available upon request

Applications

  • Immunophenotyping of T cell, NK, B cell, and monocytic compartments
  • T cell exhaustion and checkpoint receptor expression analysis
  • TCR repertoire sequencing and clonality studies
  • Ex vivo checkpoint blockade and T cell reactivation assays
  • Cytotoxicity, killing, and suppression functional assays
  • Autologous effector cells for tumor co-culture models
  • Bulk and single-cell transcriptomic and multi-omic profiling
  • Peripheral correlate discovery for immunotherapy response research

Other Kidney Cancer Specimen Types

Compliance and Quality Assurance

  • IRB-approved collections and protocols
  • 21 CFR Part 11-compliant e-consent system
  • HIPAA-compliant donor data protection

Ordering & Customization

Kidney Cancer PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse all donor cohorts and current stock, visit our human PBMCs page.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Frequently Asked Questions

Showing 1–12 of 30 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information